Home » Newsletters » BioWorld

BioWorld

Feb. 11, 1992

View Archived Issues

G-CSF Preferable in Some Cases

Regenerons CNTF Designated Orphan Drug

MEDICORP ACQUIRES TECHNOLOGY RIGHTS

FDA APPROVES ONCOR CANCER DIAGNOSTIC

INJECTABLE SMOKING DRUG ENTERS PHASE II

IPIC TO COLLABORATE WITH OHIO STATE

PROCYTE DISCUSSES WOUND-HEALING COMPOUND

ALPHA 1 TAKES $1 MILLION ORDER

STERLING WINTHROP LICENSES BIOMIRA MAbs

MGI HALTS CHEMOPROTECTIVE TRIALS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026